REG - Yourgene Health PLC - AGM Statement

Yourgene HealthAnnouncement

27/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220927:nRSa7152Aa&default-theme=true

RNS Number : 7152A  Yourgene Health PLC  27 September 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

 

AGM statement

 

Manchester, UK - 27 September 2022: Yourgene (AIM: YGEN), the international
molecular diagnostics group, will be holding its Annual General Meeting
("AGM") at 2:00pm today.

 

At the meeting, Dr John Brown CBE, Non-executive Chairman, will make the
following statement:

 

'It is a pleasure to be at my first AGM as Chairman of Yourgene after 3 years
on the Board as a Non-executive Director. I would like to thank my predecessor
Adam Reynolds for his contribution to making Yourgene the exciting business it
is today. The business is a growing force in genomic testing and is addressing
growth opportunities in non-invasive prenatal testing, oncology, reproductive
health and infectious disease, with an increasing presence in key overseas
geographies including North America, Europe and Asia.

 

We continue to see the core business performing at pre-pandemic growth levels.

 

The team has done a great job during the pandemic and, having come out the
other side, is now both better resourced and equipped. With solid progress
being made in the first half, we are now focused on a number of pipeline
opportunities that will support growth in the second half and underpin next
year's performance. The Board looks forward to updating the market at the time
of our interim results release in due course.

 

Yourgene is distinguished by its breadth of high growth value propositions,
some of which represent near-term commercial opportunities to build market
share, while others reflect truly accretive prospects to create longer-term
value, including through geographic expansion and new product or service
launches.

 

I look forward to working with the Board, shareholders, and the management
team to chart our way to delivering the best mix of these near and long term
opportunities.'

 

After the formal AGM proceedings, Lyn Rees, CEO, will provide shareholders
with a short business update ahead of the onsite Investor Open Day later in
the afternoon. The Open Day is to be held at the Company's new headquarters in
Skelton House, Manchester Science Park, M15 6SH. This is now the sole UK
business premise for Yourgene and all other locations including Citylabs have
moved to the new site.

 

The AGM will be available as a hybrid event via the Investor Meet Company
platform. Investors can sign up to Investor Meet Company for free and register
for the Yourgene Health meeting via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
(https://www.investormeetcompany.com/yourgene-health-plc/register-investor)
.

 

The presentation recording and responses to investor questions will be made
available on the Investor Meet Company platform at the earliest opportunity.

 

 

 Yourgene Health plc                                                        Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                          investors@yourgene-health.com
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)                                       Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)                                  Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
  Paul McManus / Lianne Applegarth                                          Mob: 07980 541 893 / Mob: 07584 391 303 /

  Alice Woodings                                                            Mob: 07407 804 654

 

About Yourgene Health plc

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The Yourgene Genomic Services team works with healthcare professionals,
researchers and pharmaceutical organisations to support and accelerate
scientific advances in genomic medicine. The division's specialist services
guide decisions about abnormalities, hereditary risk and treatment in addition
to providing novel insights in research and discovery. Accredited clinical
services are provided in Oncology and Reproductive Health within the UK and
worldwide. The team of scientific experts offer consultative services to help
guide partners in selecting the right technology and approach for their
applications.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMBKABBKBKBACB